It is known that there are close relationships between bone destruction and tumor growth in bone metastasis. RANKL is a central factor in bone metastasis, inducing osteoclastogenesis mediated by its ...
Researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL), led by Dr. Eva Gonzalez-Suarez, have shown that pharmacological and genetic inhibition of signaling pathway RANK / RANKL ...
An evaluation of bone marrow stromal-derived growth factor-1 and interleukin-8 levels in patients with stage I-III breast cancer with disseminated tumor cells. This is an ASCO Meeting Abstract from ...
The tumor necrosis factor (TNF) superfamily represents a large, loosely related, and versatile group of homotrimeric cytokines. There has been considerable interest in the structure of these proteins, ...
The drug denosumab is currently used to treat osteoporosis and bone metastases. For more than a decade, its potential therapeutic benefit in the treatment of breast cancer has also been studied.
Effects of concomitant therapies on γδ T-cell responses to zoledronate in patients with advanced prostate cancer. This is an ASCO Meeting Abstract from the 2014 ASCO Annual Meeting I. This abstract ...
French researchers have used a protein called receptor activator of NF-κB ligand (RANKL) to revive the structure and function of the thymus in old mice. The thymus sits in front of the heart and is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results